Format

Send to

Choose Destination
Best Pract Res Clin Haematol. 2016 Sep;29(3):252-263. doi: 10.1016/j.beha.2016.10.015. Epub 2016 Oct 20.

Making the diagnosis, the tools, and risk stratification: More than just BCR-ABL.

Author information

1
Clinical Research Division, Fred Hutchinson Cancer Research Center, United States. Electronic address: degan@fredhutch.org.
2
Clinical Research Division, Fred Hutchinson Cancer Research Center, United States. Electronic address: jradich@fredhutch.org.

Abstract

The implementation of cytogenetic and molecular techniques into standard clinical practice has improved our ability to more accurately diagnose and monitor CML. Routine peripheral blood BCR-ABL transcript testing can help monitor response, predict outcome, and detect early resistance or poor adherence to TKI therapy. The widely-used Sokal, Hasford and EUTOS clinical risk stratification scores were developed in patients receiving chemotherapy, interferon and imatinib, respectively; their predictive ability in patients receiving next-generation tyrosine kinase inhibitors (TKIs) remains to be established. Newer more sensitive molecular techniques are being developed that may aid in the expanding emphasis on discontinuing therapy in patients with a deep and consistent molecular response.

KEYWORDS:

BCR-ABL tyrosine kinase; Chronic; Cytogenetic techniques; Diagnoses and examinations; Fluorescent in situ hybridization; Leukemia; Myeloid; PCR; Philadelphia chromosome

PMID:
27839566
DOI:
10.1016/j.beha.2016.10.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center